Autolus Therapeutics plc
AUTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $21,194 | $20,923 | $8,982 | $29 |
| % Growth | 1.3% | 132.9% | 30,872.4% | – |
| Cost of Goods Sold | $28,643 | $24,445 | $17,951 | $138,304 |
| Gross Profit | -$7,449 | -$3,522 | -$8,969 | -$138,275 |
| % Margin | -35.1% | -16.8% | -99.9% | -476,810.3% |
| R&D Expenses | $27,892 | $27,430 | $26,734 | $50,530 |
| G&A Expenses | $36,280 | $30,265 | $29,534 | $67,410 |
| SG&A Expenses | $36,280 | $30,265 | $29,534 | $42,479 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$24,931 |
| Other Operating Expenses | $0 | $0 | $0 | $10,142 |
| Operating Expenses | $64,172 | $57,695 | $56,268 | $103,151 |
| Operating Income | -$71,621 | -$61,217 | -$65,237 | -$241,426 |
| % Margin | -337.9% | -292.6% | -726.3% | -832,503.4% |
| Other Income/Exp. Net | -$6,965 | $13,697 | -$2,699 | $215,282 |
| Pre-Tax Income | -$78,586 | -$47,520 | -$67,936 | -$26,144 |
| Tax Expense | $532 | $397 | $2,225 | $1,462 |
| Net Income | -$79,118 | -$47,917 | -$70,161 | -$27,606 |
| % Margin | -373.3% | -229% | -781.1% | -95,193.1% |
| EPS | -0.3 | -0.18 | -0.26 | -0.1 |
| % Growth | -66.7% | 30.8% | -160% | – |
| EPS Diluted | -0.3 | -0.18 | -0.26 | -0.1 |
| Weighted Avg Shares Out | 266,141 | 266,141 | 266,127 | 266,125 |
| Weighted Avg Shares Out Dil | 266,141 | 266,141 | 266,127 | 266,125 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,382 | $12,063 | $6,137 | $7,447 |
| Interest Expense | $10,520 | $0 | $10,143 | -$30,835 |
| Depreciation & Amortization | $3,363 | $4,311 | $2,277 | $2,077 |
| EBITDA | -$64,703 | -$56,906 | -$55,516 | -$73,787 |
| % Margin | -305.3% | -272% | -618.1% | -254,437.9% |